AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar ... (er and at 6-month intervals during chron...)

AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression

Date:2/23/2009

er, and at 6-month intervals during chronic treatment. The possibility of a suicide attempt is inherent in schizophrenia, and close supervision of high risk patients should accompany drug therapy.

The most commonly reported adverse reactions associated with the use of SEROQUEL XR vs. placebo in clinical trials for schizophrenia and bipolar disorder were somnolence (25%-52% vs. 10%-13%), dry mouth (12%-37% vs. 1%-7%), constipation (6-10% vs. 3-6%), dyspepsia (5-7% vs. 1-4%), dizziness (10-13% vs. 4-11%), orthostatic hypotension (7% vs. 5%), weight gain (7% vs. 1%), increased appetite (12% vs. 6%), fatigue (6-7% vs. 2-4%), dysarthria (5% vs. 0%), and nasal congestion (5% vs. 1%).

Please see full Prescribing Information, including Boxed Warnings, for SEROQUEL XR.

About AstraZeneca

AstraZeneca is engaged in the research, development, manufacturing and marketing of meaningful prescription medicines and in the supply of healthcare services. AstraZeneca is one of the world's leading pharmaceutical companies with global healthcare sales of $ 31.6 billion and is a leader in gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infectious disease medicines. In the United States, AstraZeneca is a $13.5 billion dollar healthcare business. For more information about AstraZeneca in the US or our AZ&Me(TM) Prescription Savings programs, please visit: www.astrazeneca-us.com.

The statements contain herein include forward-looking statements. Although we believe our expectations are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine news :

1. Palatin Technologies Announces Receipt of $4.1 Million from AstraZeneca
2. AstraZeneca Helped More Than 440,000 Patients Save $612 Million on Medicines in 2008
3. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
4. MAP Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Unit Dose Budesonide Collaboration with AstraZeneca
5. AstraZenecas Drug Will Become the New Clinical Gold Standard by 2012 for the Treatment of Metastatic Hormone-Refractory Prostate Cancer
6. AstraZeneca Settles US Pulmicort Respules Patent Litigation with Teva
7. Analyst Available to Comment on New JUPITER Study That Shows AstraZenecas Crestor Significantly Reduces CV Risk
8. AstraZenecas Purplepill.com Tops the List of Most Visited Pharmaceutical Brand Web Sites in Q2 2008
9. AstraZeneca Recognized as One of Working Mother Magazines 100 Best Companies
10. Handa Pharmaceuticals Announces Submission of its First-to-File ANDA for AstraZenecas SEROQUEL(R) XR
11. AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6

Post Your Comments:

(Date:3/14/2010)... pressure to normal levels below currently recommended ... risk of fatal or nonfatal cardiovascular disease events ... at especially high risk for cardiovascular disease events, ... to Control Cardiovascular Risk in Diabetes (ACCORD) clinical ... drug therapy of a fibrate and a statin ...

(Date:3/14/2010)... experience all the benefits of acupuncture, hypnosis and neuroprogramming without ... Wouldn,t you love to be able to Quit Smoking, Lose ... ... Lima, OH (PRWEB) March 14, 2010 -- AcuAids announces acupuncture ... ,· Key features include the ability to ...

(Date:3/13/2010)... AND ATLANTA, GA MARCH 13, 2010 ... (Evaluation of Xience Prime versus Coronary Artery Bypass ... will compare drug-eluting stents to coronary artery bypass ... artery disease, was made today at "Optimizing PCI ... Cardiovascular Research Foundation. , "While the SYNTAX trial ...

(Date:3/13/2010)... on the hearts of police, firefighters , , SATURDAY, March ... to the collapsing World Trade Center towers appear to ... people in the general population, a new study finds. ... the American College of Cardiology,s annual meeting, in Atlanta. ... potential link between exposure to Ground Zero and early ...

(Date:3/13/2010)... to high blood pressure, heart attack, even death, study ... regular exercise such as jogging is good for the ... be even better, right? , Not so fast, ... that marathon runners have increased stiffness of the large ... actually be bad for the heart, potentially leading to ...

Breaking Medicine News(10 mins):Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 2 Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 3 Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 4 Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 5 Health News:ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes 6 Health News:AcuAids Announces Acupuncture at Home to Stop Smoking, Lose Weight and More 2 Health News:AcuAids Announces Acupuncture at Home to Stop Smoking, Lose Weight and More 3 Health News:EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery 2 Health News:Many WTC Responders Show Signs of Heart Trouble 2 Health News:Many WTC Responders Show Signs of Heart Trouble 3 Health News:Marathoners Face Greater Risk of Artery Stiffness 2

[0] ACCORD: Intensive BP, combined lipid therapies do not help adults with diabetes [0] AcuAids Announces Acupuncture at Home to Stop Smoking, Lose Weight and More [0] EXCEL trial will determine safety and efficacy of drug-eluting stents vs. bypass surgery [0] Many WTC Responders Show Signs of Heart Trouble [0] Marathoners Face Greater Risk of Artery Stiffness

... 15 Quest Diagnostics Incorporated (NYSE: ... patients and their physicians to share diagnostic laboratory ... enable physicians who use Quest Diagnostics, Care360(TM) patient-centric ... request, diagnostic laboratory test results in a HIPAA-compliant ...

... CRANBURY, N.J., May 15 Palatin Technologies, Inc. (NYSE Amex: ... March 31, 2009. Palatin reported net income of $0.1 million, ... March 31, 2009, compared to a net loss of $5.1 million, ... in 2008. Total revenues in the quarter ended March 31, ...

... it has been known that aspirin is beneficial to ... of the many different types of aspirin is likely ... led by Dr. Sean Nordt from the University of ... to a group of volunteer research subjects: regular aspirin ...

... 15 /PRNewswire-Asia-FirstCall/ -- China Pharma,Holdings, Inc. ("China Pharma") (OTC Bulletin ... China, today,announced financial results for the first quarter ended March ... Financial Highlights, -- Revenue increased 10.9% to ... first quarter of 2008, ...

... to 400umol/g delivers Market Leading Economies to Reduce Synthesis Costs ... ... Calif. (PRWEB) May 15, 2009 -- Kinovate Life Sciences, Inc, ... be announcing the successful development of its next generation high ...

... The recent H1N1 influenza epidemic has raised many questions ... potential route is through veterinarians, who, according to a ... Health researchers, are at markedly increased risk of infection ... can infect both animals and humans. , While ...

Other Medicine News:Health News:Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online 2 Health News:Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online 3 Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 2 Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 3 Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 4 Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 5 Health News:Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 6 Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 2 Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 3 Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 4 Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 5 Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 6 Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 7 Health News:China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates 8 Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 2 Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 3 Health News:Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis 4 Health News:Veterinarians at high risk for viral, bacterial infections from animals 2 Health News:Veterinarians at high risk for viral, bacterial infections from animals 3

Quest Diagnostics to Connect to Microsoft HealthVault and Empower Patients and Physicians to Share Diagnostic Laboratory Test Results Online Palatin Technologies, Inc. Reports Fiscal Year 2009 Third Quarter Results; Teleconference and Webcast to be held on May 15, 2009 Study compares formulations of three aspirin types China Pharma Holdings, Inc. Reports First Quarter 2009 Financial Results and Corporate Updates Kinovate Life Sciences, Inc. and Nitto Denko Corporation Announce Successful Development of NittoPhase™ HL High Loading Solid Support for Oligonucleotide Synthesis Veterinarians at high risk for viral, bacterial infections from animals

(Date:3/12/2010)... Newswise -- What regenerative medicine therapies ... stand between stem cell therapies and real treatments ... inaugural Translational Regenerative Medicine Forum will discuss these ... various national and regional stem cell initiatives. The ... Winston-Salem , is an annual event to ...

(Date:3/12/2010)... health and creativity. History has produced a legion of great nappers. Among them are Leonardo Da Vinci , Thomas Edison and Lord Byron, ... ... , ... ... ...

(Date:3/12/2010)... LAKE, N.J. , March 12 Eisai Inc. (Headquarters: ... today announces that it has entered into a licensing agreement with the ... John Griffin , M.D., "BSI") related to Eisai,s GCPII (glutamate carboxypeptidase II) ... ... ...

Breaking Medicine Technology:Speakers to Focus on Translating Regenerative Medicine Science 2 Speakers to Focus on Translating Regenerative Medicine Science 3 Speakers to Focus on Translating Regenerative Medicine Science 4 Speakers to Focus on Translating Regenerative Medicine Science 5 Protect-A-Bed(R) Supports the Art of Napping on National Napping Day 2 Protect-A-Bed(R) Supports the Art of Napping on National Napping Day 3 Protect-A-Bed(R) Supports the Art of Napping on National Napping Day 4 Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 2 Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute 3 Raleigh Dentist Dr Robert Williamson to Educate Patients About Sedation Dentistry 62220 1 Raleigh Dentist Dr Robert Williamson to Educate Patients About Sedation Dentistry 62220 2 WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 14991 1 WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 14991 2 Sanofi aventis 3A Multaq 28R 29 Approved in the European Union for Patients With Atrial Fibrillation 6571 1 Sanofi aventis 3A Multaq 28R 29 Approved in the European Union for Patients With Atrial Fibrillation 6571 2 Sanofi aventis 3A Multaq 28R 29 Approved in the European Union for Patients With Atrial Fibrillation 6571 3 Sanofi aventis 3A Multaq 28R 29 Approved in the European Union for Patients With Atrial Fibrillation 6571 4 Sanofi aventis 3A Multaq 28R 29 Approved in the European Union for Patients With Atrial Fibrillation 6571 5

[0] Speakers to Focus on Translating Regenerative Medicine Science [0] Protect-A-Bed(R) Supports the Art of Napping on National Napping Day [0] Eisai Enters Licensing Agreement with Johns Hopkins Brain Science Institute

... in Fourth Quarter, BERKELEY HEIGHTS, N.J., March ... that the Data Safety Monitoring Board,(DSMB) for AGENDA, ... which is the Company,s lead oncology product, has ... after initial review of,blinded safety data from the ...

... of action -, CHICAGO, March 31 CV ... significantly (p<0.001),shortened the QT interval of patients with a ... caused by a genetic mutation in the late,sodium channel ... death. Ranolazine also shortened cardiac relaxation time in the,study., ...

Other Medicine Technology:DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 2 DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 3 DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma 4 Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 2 Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder 3

DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma Ranolazine Shortens QT Interval and Improves Cardiac Relaxation in Study of Patients With Genetic Sodium Channel Disorder

... line of flowmeters, available in oxygen, air, heliox and ... variety of calibrations to best suit your application. With ... in use, the Amvex Flowmeter is a user friendly ... I. For Power Take-Off add PT to the end ...

... available in oxygen, air, heliox and CO 2 . ... to best suit your application. With color coded labels ... Amvex Flowmeter is a user friendly device., ,For ... Take-Off add PT to the end of the part ...

0-3.5 LPM Oxygen Flowmeter 1/8" NPT Female inlet...

(1/2-8 LPM), 50 psi, 1/ 8" NPT female back inlet...

Medicine Products:

Tube Style Oxygen Flowmeters - Puritan Bennett Tube Style Oxygen Flowmeters - Diss Handtight 0-3.5 LPM Oxygen Flowmeter - 1/8" NPT Female Inlet Pediatric Oxygen Flowmeter (Cylindrical Style)

AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar ...(er and at 6-month intervals during chron...),Health